Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases

European Respiratory Review

Volumn 27, Issue 150, 2018, Pages

  Cottin, Vincent ^a   Hirani, Nikhil A ^b   Hotchkin, David L ^c   Nambiar, Anoop M ^d   Ogura, Takashi ^e   Otaola, María ^f   Skowasch, Dirk ^g   Park, Jong Sun ^h   Poonyagariyagorn, Hataya K ^c   Wuyts, Wim ⁱ   Wells, Athol U ^j  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Oregon Clinic   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^f Instituto de Rehabilitacion Psicofísica IREP Hospital   (Argentina)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC PNEUMONITIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; EARLY DIAGNOSIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG SARCOIDOSIS; OCCUPATIONAL EXPOSURE; RADIOLOGICAL PARAMETERS; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; ADULT; AGED; DIAGNOSTIC IMAGING; FEMALE; LUNG; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; QUALITY OF LIFE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY FIBROSIS; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85058921596     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0076-2018     Document Type: Review

References (115)

1. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4: e000212.
2. Mikolasch TA, Porter JC. Transbronchial cryobiopsy in the diagnosis of interstitial lung disease: a cool new approach. Respirology 2014; 19: 623–624.
3. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Respir Dis 2011; 8: 225–231.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
5. Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017; 3: 17074.
6. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017; 389: 1941–1952.
7. Kreuter M, Walscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med 2017; 23: 418–425.
8. Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev 2013; 22: 6–19.
9. Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692.
10. Olson AL, Brown KK, Swigris JJ. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas 2016; 7: 29–35.
11. Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res 2018; 19: 32.
12. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: Suppl. 5, v1–v58.
13. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976–987.
14. Strek ME, Costabel U. Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition. Curr Opin Pulm Med 2016; 22: 442–449.
15. De Sadeleer LJ, Meert C, Yserbyt J, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest 2018; 153: 1416–1423.
16. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
17. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42: 750–757.
18. Humphries SM, Yagihashi K, Huckleberry J, et al. Idiopathic pulmonary fibrosis: data-driven textural analysis of extent of fibrosis at baseline and 15-month follow-up. Radiology 2017; 285: 270–278.
19. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Unclassifiable-interstitial lung disease: outcome prediction using CT and functional indices. Respir Med 2017; 130: 43–51.
20. Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180073.
21. Buzan MT, Pop CM. State of the art in the diagnosis and management of interstitial lung disease. Clujul Med 2015; 88: 116–123.
22. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382–1389.
23. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543–548.
24. Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 2018; 73: 391–392.
25. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 639–644.
26. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33: 68–76.
27. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830–836.
28. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531–537.
29. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015; 24: 102–114.
30. Neurohr C, Behr J. Changes in the current classification of IIP: a critical review. Respirology 2015; 20: 699–704.
31. Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141: 222–231.
32. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177: 1338–1347.
33. Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21: 259–268.
34. Sverzellati N, Lynch DA, Hansell DM, et al. American Thoracic Society-European Respiratory Society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographics 2015; 35: 1849–1871.
35. Yamakawa H, Kitamura H, Takemura T, et al. Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. Respirology 2018; 23: 1032–1040.
36. Takahashi M, Kunugi S, Terasaki Y, et al. The difference of neovascularization in early intra-alveolar fibrosis between nonspecific interstitial pneumonia and usual interstitial pneumonia. Pathol Int 2013; 63: 237–244.
37. Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J 2015; 45: 746–755.
38. Kambouchner M, Levy P, Nicholson AG, et al. Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 2014; 65: 549–560.
39. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199–203.
40. Lee SH, Park MS, Kim SY, et al. Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study. Respir Res 2017; 18: 204.
41. Travis WD, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24: 19–33.
42. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
43. Hyldgaard C, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology 2017; 22: 494–500.
44. Nakamura Y, Sugino K, Kitani M, et al. Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias. Respir Investig 2018; 56: 40–47.
45. Traila D, Oancea C, Tudorache E, et al. Clinical profile of unclassifiable interstitial lung disease: comparison with chronic fibrosing idiopathic interstitial pneumonias. J Int Med Res 2018; 46: 448–456.
46. Skolnik K, Ryerson CJ. Unclassifiable interstitial lung disease: a review. Respirology 2016; 21: 51–56.
47. Wells AU, Denton CP. Interstitial lung disease in connective tissue disease – mechanisms and management. Nat Rev Rheumatol 2014; 10: 728–739.
48. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 2016; 21: 245–258.
49. Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am 2015; 41: 225–236.
50. Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33: 882–896.
51. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352: h6819.
52. Ahmad K, Barba T, Gamondes D, et al. Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017; 123: 56–62.
53. Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793–799.
54. Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J 2016; 47: 1535–1558.
55. Wuyts WA, Cavazza A, Rossi G, et al. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev 2014; 23: 308–319.
56. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580–1588.
57. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397–1405.
58. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625–631.
59. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583–1591.
60. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372–378.
61. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76: 1700–1706.
62. Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol 2017; 29: 254–259.
63. Smith M, Dalurzo M, Panse P, et al. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol 2013; 66: 896–903.
64. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019–2027.
65. Hozumi H, Nakamura Y, Johkoh T, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 2013; 3: e003132.
66. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322–1328.
67. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705–711.
68. Moua T, Zamora Martinez AC, Baqir M, et al. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014; 15: 154.
69. Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2018; in press [https://doi.org/10.1183/13993003.00869-2018].
70. Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155–160.
71. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.
72. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246–2255.
73. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809–1815.
74. Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015; 24: 411–419.
75. Pattanaik D, Brown M, Postlethwaite BC, et al. Pathogenesis of systemic sclerosis. Front Immunol 2015; 6: 272.
76. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560–567.
77. Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015; 41: 237–248.
78. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581–1586.
79. Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008; 134: 601–605.
80. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014; 146: 422–436.
81. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186: 314–324.
82. Sforza GG R, Marinou A. Hypersensitivity pneumonitis: a complex lung disease. Clin Mol Allergy 2017; 15: 6.
83. Takemura T, Akashi T, Ohtani Y, et al. Pathology of hypersensitivity pneumonitis. Curr Opin Pulm Med 2008; 14: 440–454.
84. Kouranos V, Jacob J, Nicholson A, et al. Fibrotic hypersensitivity pneumonitis: key issues in diagnosis and management. J Clin Med 2017; 6: pii.
85. Vasakova M, Morell F, Walsh S, et al. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med 2017; 196: 680–689.
86. Fernandez Perez ER, Swigris JJ, Forssen AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644–1651.
87. Jacob J, Bartholmai BJ, Brun AL, et al. Evaluation of visual and computer-based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis. Respirology 2017; 22: 1585–1591.
88. Jeong YJ, Lee KS, Chung MP, et al. Chronic hypersensitivity pneumonitis and pulmonary sarcoidosis: differentiation from usual interstitial pneumonia using high-resolution computed tomography. Semin Ultrasound CT MR 2014; 35: 47–58.
89. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1: 685–694.
90. Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. where we stand and where we need to go. Am J Respir Crit Care Med 2017; 196: 690–699.
91. Silva CI, Muller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008; 246: 288–297.
92. Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22: 1672–1679.
93. Sahin H, Brown KK, Curran-Everett D, et al. Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival. Radiology 2007; 244: 591–598.
94. Glazer CS. Chronic hypersensitivity pneumonitis: important considerations in the work-up of this fibrotic lung disease. Curr Opin Pulm Med 2015; 21: 171–177.
95. Morisset J, Johannson KA, Jones KD, et al. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi survey. Am J Respir Crit Care Med 2017; in press https://doi.org/10.1164/rccm.201710-1986OC.
96. Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest 2014; 145: 1333–1338.
97. Olson AL, Huie TJ, Groshong SD, et al. Acute exacerbations of fibrotic hypersensitivity pneumonitis: a case series. Chest 2008; 134: 844–850.
98. Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 2013; 144: 586–592.
99. Vourlekis JS, Schwarz MI, Cherniack RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 2004; 116: 662–668.
100. Hanak V, Golbin JM, Hartman TE, et al. High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008; 134: 133–138.
101. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis. Eur Radiol 2017; 27: 3635–3646.
102. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013; 10: 362–370.
103. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573–581.
104. Patterson KC, Chen ES. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest 2017; 153: 1432–1442.
105. Salvatore M, Ishikawa G, Padilla M. Is it idiopathic pulmonary fibrosis or not? J Am Board Fam Med 2018; 31: 151–162.
106. Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38: 1368–1373.
107. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691–715.
108. Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Curr Opin Pulm Med 2015; 21: 193–200.
109. Leung CC, Yu IT, Chen W. Silicosis. Lancet 2012; 379: 2008–2018.
110. Castranova V, Vallyathan V. Silicosis and coal workers’ pneumoconiosis. Environ Health Perspect 2000; 108: Suppl. 4, 675–684.
111. Arakawa H, Johkoh T, Honma K, et al. Chronic interstitial pneumonia in silicosis and mix-dust pneumoconiosis: its prevalence and comparison of CT findings with idiopathic pulmonary fibrosis. Chest 2007; 131: 1870–1876.
112. Arakawa H, Fujimoto K, Honma K, et al. Progression from near-normal to end-stage lungs in chronic interstitial pneumonia related to silica exposure: long-term CT observations. AJR Am J Roentgenol 2008; 191: 1040–1045.
113. Larsen BT, Smith ML, Elicker BM, et al. Diagnostic approach to advanced fibrotic interstitial lung disease: bringing together clinical, radiologic, and histologic clues. Arch Pathol Lab Med 2017; 141: 901–915.
114. Cullinan P, Reid P. Pneumoconiosis. Prim Care Respir J 2013; 22: 249–252.
115. Bang KM, Mazurek JM, Wood JM, et al. Diseases attributable to asbestos exposure: years of potential life lost, United States, 1999–2010. Am J Ind Med 2014; 57: 38–48.